• MDxHealth posted Q1 revenue of USD 27.4 million, up 13% year over year, while net loss narrowed to USD 8.9 million.
• Operating loss widened to USD 7.3 million, while gross margin slipped 3.1 percentage points to 60.7%.
• Test volumes diverged, with tissue-based volume falling 12% to 11,110, while liquid-based volume more than doubled to 26,235.
• Company will exit Resolve UTI and shut laboratory operations in Plano, Texas, citing an uncertain reimbursement landscape tied to a policy reversal by Medicare administrator Novitas; cash and cash equivalents ended quarter at USD 43.2 million.
• Updated 2026 revenue guidance for core cancer business excluding Resolve set at USD 110-115 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131600PRIMZONEFULLFEED1001181882) on May 13, 2026, and is solely responsible for the information contained therein.